You have free access to this content

British Journal of Clinical Pharmacology

Cover image for Vol. 59 Issue 4

April 2005

Volume 59, Issue 4

Pages 377–490

  1. Editors’ view

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Drug development: more science, more education (pages 377–378)

      J. K. Aronson

      Version of Record online: 30 MAR 2005 | DOI: 10.1111/j.0306-5251.2005.02420.x

  2. Pharmacodynamics

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Measuring bronchodilation in COPD clinical trials (pages 379–384)

      Z. L. Borrill, C. M. Houghton, A. A. Woodcock, J. Vestbo and D. Singh

      Version of Record online: 24 JAN 2005 | DOI: 10.1111/j.1365-2125.2004.02261.x

      • image
    2. You have free access to this content
    3. You have free access to this content
  3. Pharmacokinetics

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Absence of circadian variation in the pharmacokinetics of lopinavir/ritonavir given as a once daily dosing regimen in HIV-1-infected patients (pages 398–404)

      R. P. G. Van Heeswijk, M. Bourbeau, I. Seguin, P. Giguere, G. E. Garber and D. W. Cameron

      Version of Record online: 9 FEB 2005 | DOI: 10.1111/j.1365-2125.2005.02337.x

      • image
      • image
  4. Pharmacokinetics and Pharmacodynamics

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects (pages 405–414)

      Béatrice Astruc, Antoine Tarral, Philippe Dostert, Fabrizia Mariotti, Laura Fabbri and Bruno P. Imbimbo

      Version of Record online: 9 FEB 2005 | DOI: 10.1111/j.1365-2125.2005.02338.x

      • image
      • image
      • image
  5. Pharmacogenetics

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer (pages 415–424)

      Qingyu Zhou, Alex Sparreboom, Eng-Huat Tan, Yin-Bun Cheung, Ann Lee, Donald Poon, Edmund J. D. Lee and Balram Chowbay

      Version of Record online: 9 FEB 2005 | DOI: 10.1111/j.1365-2125.2004.02330.x

      • image
      • image
  6. Drug interactions

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects (pages 425–432)

      Xuemin Jiang, Kenneth M. Williams, Winston S. Liauw, Alaina J. Ammit, Basil D. Roufogalis, Colin C. Duke, Richard O. Day and Andrew J. McLachlan

      Version of Record online: 9 FEB 2005 | DOI: 10.1111/j.1365-2125.2005.02322.x

      • image
      • image
      • image
    2. You have free access to this content
      Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects (pages 433–439)

      Jari J. Lilja, Janne T. Backman and Pertti J. Neuvonen

      Version of Record online: 22 DEC 2004 | DOI: 10.1111/j.1365-2125.2004.02323.x

      • image
      • image
      • image
    3. You have free access to this content
      Diltiazem inhibits human intestinal cytochrome P450 3A (CYP3A) activity in vivo without altering the expression of intestinal mRNA or protein (pages 440–446)

      A. G. Pinto, J. Horlander, N. Chalasani, M. Hamman, A. Asghar, D. Kolwankar and S. D. Hall

      Version of Record online: 20 JAN 2005 | DOI: 10.1111/j.1365-2125.2005.02343.x

      • image
      • image
      • image
  7. Therapeutics

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
  8. Drug utilisation

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Ineffectiveness of lipid-lowering therapy in primary care (pages 456–463)

      E. Van Ganse, T. Souchet, L. Laforest, P. Moulin, M. Bertrand, P. Le Jeunne, N. Travier, D. Yin, E. Alemao and G. De Pouvourville

      Version of Record online: 9 FEB 2005 | DOI: 10.1111/j.1365-2125.2005.02266.x

      • image
  9. Education

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
  10. Short reports

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Therapeutic innovation in the European Union: analysis of the drugs approved by the EMEA between 1995 and 2003 (pages 475–478)

      Domenico Motola, Fabrizio De Ponti, Pasqualino Rossi, Nello Martini and Nicola Montanaro

      Version of Record online: 22 DEC 2004 | DOI: 10.1111/j.1365-2125.2004.02320.x

      • image
    2. You have free access to this content
      Raloxifene pharmacokinetics in males with normal and impaired renal function (pages 479–482)

      David Czock, Frieder Keller, Mette Heringa and Franz Maximilian Rasche

      Version of Record online: 20 JAN 2005 | DOI: 10.1111/j.1365-2125.2004.02326.x

      • image
    3. You have free access to this content
      Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors (pages 483–485)

      H. Schelleman, O. H. Klungel, C. M. Van Duijn, J. C. M. Witteman, A. Hofman, A. De Boer and B. H. Ch Stricker

      Version of Record online: 22 DEC 2004 | DOI: 10.1111/j.1365-2125.2004.02332.x

      • image
  11. Letters to the editors

    1. Top of page
    2. Editors’ view
    3. Pharmacodynamics
    4. Pharmacokinetics
    5. Pharmacokinetics and Pharmacodynamics
    6. Pharmacogenetics
    7. Drug interactions
    8. Therapeutics
    9. Drug utilisation
    10. Education
    11. Short reports
    12. Letters to the editors
    1. You have free access to this content
      Co-administration of oxycodone and morphine and analgesic synergy re-examined (pages 486–487)

      Maree T. Smith and Felix A. De La Iglesia

      Version of Record online: 30 MAR 2005 | DOI: 10.1111/j.1365-2125.2005.02345_1.x

      • image
    2. You have free access to this content
      Response to Smith MT and de la Iglesia FA: ‘Coadministration of oxycodone and morphine and analgesic synergy re-examined.’ (pages 487–488)

      Michael Grath, Wattan Massalha, Dorit Pud, Rivka Adler and Elon Eisenberg

      Version of Record online: 30 MAR 2005 | DOI: 10.1111/j.1365-2125.2005.02345_2.x

    3. You have free access to this content
      Different accumulation of temocapril and enalapril during repeated dosing in elderly patients (pages 489–490)

      Masashi Arakawa, Masami Ohmori, Ken-ichi Harada, Nobutaka Araki, Tetsuo Saitoh and Akio Fujimura

      Version of Record online: 20 JAN 2005 | DOI: 10.1111/j.1365-2125.2005.02346.x

      • image

SEARCH

SEARCH BY CITATION